Ortho Clinical Diagnostics Holdings plc OCDX
Apr 24, 2025, 3:47 PM EDT
52-week range unavailable
- Revenue (ttm)
- 2.04B
- Profit margin
- -0.02%
- Shares out
- 237.74M
- Forward P/E
- 17.46
- Volume
- 789.49K
- Open
- 17.68
- Previous close
- 17.63
- Day's range
- 17.36 – 17.71
- Analysts
- Hold
- Price target
- 20.96 (+18.9%)
- Earnings date
- May 4, 2022
Key statistics
- Enterprise value
- 6.17B
- PEG ratio
- 0.47
- Price / sales
- 2.06
- Price / book
- 9.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.30%
- Free cash flow
- 399.98M
- Total cash
- 281.10M
- Total debt
- 2.26B
- Return on equity
- -0.10%
- Short % of float
- 5.91%
- 50-day average
- 18.10
- 200-day average
- 18.76
Analyst view
Consensus: hold
- Target (low)
- 18.19
- Target (mean)
- 20.96
- Target (high)
- 24.68
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
May 4, 2022
Expected May 4, 2022. Consensus EPS estimate 0.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 4, 2022 | Mar 1, 2022 | 0.20 | — | — | — |
| Feb 16, 2022 | Dec 1, 2021 | 0.15 | — | — | — |
| Nov 3, 2021 | Sep 1, 2021 | 0.14 | — | — | — |
| Aug 4, 2021 | Jun 1, 2021 | 0.14 | — | — | — |
| May 5, 2021 | Mar 1, 2021 | 0.19 | — | — | — |
| Mar 18, 2021 | Dec 1, 2020 | 0.29 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 6, 2022 | Morgan Stanley | main | — | Equal-Weight |
| Feb 17, 2022 | Evercore ISI Group | up | In-Line | Outperform |
| Dec 27, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 27, 2021 | Barclays | down | Overweight | Equal-Weight |
| Dec 23, 2021 | Evercore ISI Group | down | Outperform | In-Line |
| Aug 5, 2021 | HC Wainwright & Co. | main | — | Buy |
About Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey. As of May 27, 2022, Ortho Clinical Diagnostics Holdings plc operates as a subsidiary of Quidel Corporation.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- orthoclinicaldiagnostics.com
News
Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Chris Smith on Q1 2022 Results - Earnings Call Transcript 
Earnings Scheduled For May 4, 2022 
Why Ortho Clinical (OCDX) Could Beat Earnings Estimates Again 
OCDX vs. DOCS: Which Stock Is the Better Value Option? 
Ortho Clinical (OCDX) Upgraded to Strong Buy: Here's What You Should Know 
New Strong Buy Stocks for March 24th 
OCDX vs. PGNY: Which Stock Should Value Investors Buy Now? 
ORTHO CLINICAL INVESTOR ALERT - Kuznicki Law PLLC Investigates Adequacy of Price and Process in Proposed Sale of Ortho Clinical Diagnostics Holdings plc - OCDX 
Will Ortho Clinical (OCDX) Gain on Rising Earnings Estimates? 
New Strong Buy Stocks for February 18th
Your note
Sign in to keep a note on OCDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BECHTEL KAREN H. | Director | Stock Award(Grant) | May 2, 2021 | 5,200 |
| CARLYLE GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 13, 2021 | 0 |
| DILSAVER EVELYN S | Director | Stock Award(Grant) | May 2, 2021 | 5,200 |
| HULL CARL W | Director | Stock Award(Grant) | May 2, 2021 | 62,183 |
| ISKRA MICHAEL S. | Officer | Stock Award(Grant) | May 20, 2021 | 150,000 |
| LABRUM RONALD K | Director | Stock Award(Grant) | May 2, 2021 | 109,985 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Carlyle Group Inc. | 49.68% | 118,106,000 | 2.20B | Mar 30, 2022 |
| Price (T.Rowe) Associates Inc | 8.20% | 19,489,153 | 363.67M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 4.65% | 11,047,197 | 206.14M | Mar 30, 2022 |
| Blackrock Inc. | 3.60% | 8,564,333 | 159.81M | Mar 30, 2022 |
| JP Morgan Chase & Company | 3.59% | 8,543,032 | 159.41M | Mar 30, 2022 |
| Versor Investments, LP | 2.17% | 5,163,657 | 96.35M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Triton Fund | 2.98% | 7,083,673 | 151.52M | Dec 30, 2021 |
| Price (T.Rowe) Mid Cap Growth Fund | 2.52% | 5,988,400 | 128.09M | Dec 30, 2021 |
| Price (T.Rowe) Health Sciences Fund | 1.48% | 3,513,239 | 75.15M | Dec 30, 2021 |
| JP Morgan Small Cap Equity Fund | 1.47% | 3,490,609 | 74.66M | Dec 30, 2021 |
| Vanguard Total Stock Market Index Fund | 1.42% | 3,365,328 | 71.98M | Dec 30, 2021 |
| Vanguard Small-Cap Index Fund | 1.25% | 2,976,685 | 63.67M | Dec 30, 2021 |